Next Article in Journal
PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes—Implications for UV-Induced DNA Repair and Photocarcinogenesis
Next Article in Special Issue
Oncogenic K-ras Induces Mitochondrial OPA3 Expression to Promote Energy Metabolism in Pancreatic Cancer Cells
Previous Article in Journal
Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia
Previous Article in Special Issue
Sestrins as a Therapeutic Bridge between ROS and Autophagy in Cancer
Open AccessReview

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy

Department of Chemistry, Ulsan National Institute of Science and Technology, Ulsan 44919, Korea
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 4; https://doi.org/10.3390/cancers12010004
Received: 3 November 2019 / Revised: 6 December 2019 / Accepted: 16 December 2019 / Published: 18 December 2019
(This article belongs to the Special Issue Mitochondria and Cancer)
The mitochondrion is a dynamic eukaryotic organelle that controls lethal and vital functions of the cell. Being a critical center of metabolic activities and involved in many diseases, mitochondria have been attracting attention as a potential target for therapeutics, especially for cancer treatment. Structural and functional differences between healthy and cancerous mitochondria, such as membrane potential, respiratory rate, energy production pathway, and gene mutations, could be employed for the design of selective targeting systems for cancer mitochondria. A number of mitochondria-targeting compounds, including mitochondria-directed conventional drugs, mitochondrial proteins/metabolism-inhibiting agents, and mitochondria-targeted photosensitizers, have been discussed. Recently, certain drug-free approaches have been introduced as an alternative to induce selective cancer mitochondria dysfunction, such as intramitochondrial aggregation, self-assembly, and biomineralization. In this review, we discuss the recent progress in mitochondria-targeted cancer therapy from the conventional approach of drug/cytotoxic agent conjugates to advanced drug-free approaches. View Full-Text
Keywords: mitochondria; cancer; drug conjugates; drug-free approach mitochondria; cancer; drug conjugates; drug-free approach
Show Figures

Figure 1

MDPI and ACS Style

Jeena, M.; Kim, S.; Jin, S.; Ryu, J.-H. Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy. Cancers 2020, 12, 4.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop